SEC Filing Summary: AspenBio Pharma, Inc. (10-Q)
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for AspenBio Pharma, Inc. for the period ended September 30, 2010. The company is a biopharmaceutical firm focused on developing diagnostic tests (specifically the AppyScore appendicitis test) and animal health products (BoviPure). The filing notes a strategic decision made in late 2009 to suspend antigen production to focus resources on the appendicitis project and single-chain animal product development.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 |
|---|---|---|
| Sales | $80,483 | $281,748 |
| Cost of Sales | $150,367 | $249,893 |
| Gross Profit (Loss) | $(69,884) | $31,855 |
| Operating Expenses | $2,975,177 | $10,332,192 |
| Net Loss | $(3,052,050) | $(10,345,736) |
| Cash and Cash Equivalents | $8,922,955 (Sep 30, 2010) | N/A |
| Working Capital | $12,003,576 (Sep 30, 2010) | N/A |
| Total Debt (Notes Payable) | $2,679,921 (Sep 30, 2010) | N/A |
Liquidity: The company reported a net decrease in cash of approximately $4.44 million for the nine-month period. However, a registered direct offering in May 2010 generated approximately $9.12 million in net proceeds, bolstering the cash position.
Material Changes vs. Prior Period
- Revenue: Sales for the nine months ended September 30, 2010, increased by 27% ($59,000) compared to the prior year, primarily due to the timing of customer orders before the suspension of antigen production.
- Cost of Sales: Cost of sales decreased by 18% ($54,000) year-over-year. However, the three-month period saw an 803% increase in cost of sales due to a $103,000 write-down of antigen raw materials.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by 34% ($1.5 million) for the nine-month period. This was driven by additional management hiring for the AppyScore project ($441,000), increased stock-based compensation ($720,000), higher insurance costs ($191,000), and legal fees related to pending litigation ($157,000).
- R&D Expenses: Research and development expenses decreased by 26% ($1.5 million) year-over-year, largely due to the completion of the AppyScore clinical trial and substantial completion of cassette and reader program development.
Guidance, Outlook, and Risks
Outlook: Management believes current working capital is sufficient to support operations and technology development in the near term. The primary focus remains on advancing the AppyScore test and single-chain animal-health hormone products. Capital expenditures for the remainder of 2010 are anticipated to be between $100,000 and $200,000.
Risks and Contingencies:
- Legal Proceedings: Two securities-related complaints were filed in late 2010 (one individual, one class action) alleging fraud and misrepresentation regarding the AppyScore test. The company intends to vigorously defend against these claims.
- Regulatory Risk: Future revenue generation is heavily dependent on obtaining FDA clearance for the AppyScore test. Failure to achieve this could result in impairment of development costs.
- License Agreements: The company relies on a Novartis license agreement for animal health products. A pilot study under this agreement was recently completed, with data evaluation expected in 2010. Novartis retains the right to request a refund of $900,000 if the pilot study is not successful.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the current cash position given the net loss of $10.3 million for the nine-month period and the cessation of antigen production revenue.
- AppyScore FDA Status: Confirm the timeline and probability of FDA clearance for the AppyScore test, as this is the primary driver for future valuation.
- Legal Exposure: Monitor the status of the two securities lawsuits filed in September and October 2010 regarding AppyScore disclosures.
- Novartis Milestone: Track the outcome of the Novartis pilot study evaluation, as failure could trigger a $900,000 refund obligation and termination of the agreement.
- Stock-Based Compensation: Review the impact of the $1.85 million in non-cash stock-based compensation on future dilution and expense recognition.